SANOFI

Overview

Sanofi is a Paris-headquartered global healthcare and biopharma company engaged in the research, development, manufacture, and marketing of therapeutic solutions.[1] Its core business is organized around three main biopharma franchises—Specialty Care, General Medicines, and Vaccines—which define the company’s product focus across global markets.[2] Sanofi says it is focused on patient needs, and states its purpose as “chasing the miracles of science to improve people’s lives.”[1][3]

Sanofi operates at global scale: in FY 2024 it reported net sales of €41.1 billion and employed 82,878 people worldwide.[4][5] The company has business operations in approximately 63 countries and its products are available in more than 160 countries, with major markets including the United States, Europe, Japan, and China.[6]+3 [1]+8

Products & services

Sanofi’s product portfolio is centered on biopharma medicines and vaccines. Its largest product is Dupixent, a fully human monoclonal antibody that blocks IL-4 and IL-13 and is used across type-2 inflammatory diseases including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.[10] In rare diseases, Altuviiio is a high-sustained factor VIII therapy for hemophilia A designed for once-weekly prophylaxis.[11] Other marketed specialty and general medicines include Aubagio, a once-daily oral teriflunomide treatment for multiple sclerosis; Plavix, a clopidogrel ADP receptor antagonist for prevention of atherothrombotic events; and diabetes products such as Lantus (insulin glargine 100 U/mL), Toujeo (insulin glargine 300 U/mL), and Soliqua/iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide for type 2 diabetes.[12]+4

Sanofi’s vaccines portfolio includes Beyfortus, a long-acting monoclonal antibody (nirsevimab-alip) intended to protect neonates and infants during their first RSV season and certain vulnerable children during their second season.[17] Its pediatric and travel/endemic vaccine products include Vaxelis, a hexavalent vaccine against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B, and MenQuadfi, a quadrivalent meningococcal conjugate vaccine covering serogroups A, C, W and Y.[18][19] Sanofi also markets seasonal influenza vaccines, and in 2024 it shifted the U.S. market from quadrivalent to trivalent influenza vaccines while a broader move back to trivalent formulations was underway globally.[20]

The company discloses product-level sales within Biopharma, which totaled €41.1 billion in 2024.[21] Dupixent generated €13.1 billion, equal to about 31.8% of Biopharma sales; Beyfortus generated €1.686 billion, about 4.1%; Altuviiio €682 million, about 1.7%; Lantus €1.628 billion, about 4.0%; Toujeo €1.227 billion, about 3.0%; Soliqua €227 million, about 0.6%; Plavix €914 million, about 2.2%; and influenza vaccines €2.555 billion, about 6.2%.[21] In addition to marketed products, Sanofi also records manufacturing revenue on behalf of Opella, its consumer healthcare business, separately within other revenues.[22] [10]+12

Geographic presence

Sanofi is headquartered in Paris, France, with its registered office at 46, avenue de la Grande Armée, 75017 Paris, and its principal U.S. subsidiary office at 55 Corporate Drive, Bridgewater, New Jersey. The company states that it operates office, research, production and logistics facilities in approximately 70 countries.[23]+2

Sanofi reports net sales geographically based on the customer’s location. In 2024, net sales were €19,986 million in the United States, €9,027 million in Europe, and €12,068 million in the Rest of the World, including €2,666 million in China; this made the United States its largest sales geography.[26][27]

The company employed 82,878 people worldwide in 2024, with 41,193 in Europe, 12,898 in the United States, and 28,787 in the Rest of the World. Its industrial footprint included 52 production sites in 24 countries, and it identifies biotech hubs in Paris/Lyon, Frankfurt, Geel and the Boston area. Pharmaceuticals R&D sites are listed in France, Germany/Belgium, the United States and China, while vaccines R&D sites are listed in the United States, France and Canada.[5]+10 [23]+15

Business segments

Sanofi’s current official segment reporting is centered on one continuing operating segment, Biopharma, which includes the Specialty Care, General Medicines and Vaccines franchises; a residual “Other” category mainly contains Consumer Healthcare activities not transferred with Opella. On this basis, 2024 continuing-operations net sales were entirely Biopharma at €41.1 billion, or about 100% of reported segment sales, while “Other” had no reported net sales.[38]+4

On Sanofi’s previous reporting basis, the company disclosed two main segments: Biopharma and Consumer Healthcare. In 2023’s original presentation, Biopharma generated €37.9 billion of net sales, or about 88% of group sales, while Consumer Healthcare generated €5.2 billion, or about 12%.[43]+2

For a more detailed business breakdown, Sanofi also organizes Biopharma around three franchises. Specialty Care focuses on immunology, neuro-inflammation, rare diseases and oncology; Vaccines is organized around influenza, meningitis, polio/pertussis/Hib & boosters, and RSV; and General Medicines covers Sanofi’s established-medicines platform, including areas such as diabetes and cardiovascular disease. Using the 2024 product-level sales appendix, these franchises contributed approximately €21.8 billion, €11.0 billion and €8.3 billion, respectively, equivalent to about 53%, 27% and 20% of 2024 Biopharma sales. In 2023, the comparable franchise mix was about €18.0 billion, €12.4 billion and €7.5 billion, or roughly 48%, 33% and 20% of Biopharma sales.[46]+6 [38]+13

Company history

Sanofi traces its modern origins to 1973, when Sanofi was created as a subsidiary of Elf Aquitaine. The company expanded over the following decades and, in 1999, merged with Synthélabo to form Sanofi-Synthélabo, a major step in building the group’s modern pharmaceutical platform [51].

A defining milestone came in 2004, when Sanofi-Synthélabo acquired Aventis, creating Sanofi-Aventis and establishing one of the world’s largest pharmaceutical groups [51][52]. The company later simplified its identity and has operated under the commercial name Sanofi since May 2011 [24].

The 2011 acquisition of Genzyme marked another important stage in Sanofi’s development, strengthening its position in biotechnology and rare diseases [53][54]. In its own filings, Sanofi describes the group’s later evolution as shaped by a series of acquisitions and divestments after 2011, reflecting a continued reshaping of the business around its core healthcare activities [54]. [24]+4

Sources

• SANOFI — Full financial report (2024 Y)
  45 citations

  [1][2][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][46][47][49][53][54]
• www.sanofi.com[3]
• SANOFI — Press release (2024 Y)[4]
• SANOFI — Full financial report (2023 Y)
  4 citations

  [43][44][45][50]
• www.sanofi.com[48]
• www.sanofi.com[51]
• www.ftc.gov[52]